key: cord-0839063-nd7h0cmq
authors: Betancur, Adrián Mira; De Pablo Pajares, Angélica
title: Non-Invasive Respiratory Support in the Management of COVID-19: Report of a Series Using a Nasal CPAP Mask
date: 2021-05-08
journal: Trends in Anaesthesia and Critical Care
DOI: 10.1016/j.tacc.2021.04.008
sha: 4373b858d08d55a885023ed468754ff544ebd2dd
doc_id: 839063
cord_uid: nd7h0cmq

Background During peak pandemic period of COVID-19, our hospital required rapid reorganization of resources and staff during between mid-March and early April, 2020. Within this interval, the hospital responded to an overwhelming rate of admissions of patients in respiratory failure, rapidly reaching over 95% of its usual inpatient bed capacity and requiring 70 extra critical care beds and at least 40 intermediate care unit beds. This created a significant shortage of materials including ventilation equipment, requiring improvised use of available resources. Aims To describe our use of non-invasive ventilation (NIV) with the continuous positive nasal airway pressure (CPAP) device SuperNO2VA™ (Vyaire Medical, Mettawa, IL) with hospitalized patients in acute respiratory failure due to presumed COVID-19. Methods We performed a retrospective analysis of 14 inpatients receiving NIV CPAP at the Hospital Ramón y Cajal in Madrid, Spain. These were inpatients presenting in respiratory failure during the peak pandemic period based on defined respiratory health, oxygenation, and comorbidity status criteria. Patient data were retrospectively acquired from patient medical records. Results All 14 patients were reviewed. Our series consisted of 11 males and three females with an average age of 61.5 years. Ten of 14 patients (71.4%) NIV CPAP patients did not require intubation or reintubation. Of the four unsuccessful cases, one required intubation, two required reintubation, and one expired. Conclusions In a time of crisis, anesthesiologists and respiratory specialists implemented the use of NIV CPAP with SuperNO2VA to help meet the high care demand of patients in respiratory distress. Although the SuperNO2VA was not originally developed for the management of patients in respiratory failure or distress related to COVID-19, this case series demonstrates it can be used with mostly favorable results during a time of limited resources to improve the clinical situation in patients. Advantages and disadvantages are explored.

On March 11, 2020 , the World Health Organization (WHO) declared an infection caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) as a pandemic.

[1] The WHO reported the first case in Spain on February 1, 2020, and Madrid, with almost 7 million inhabitants, reported its first case on February 25, 2020. [2, 3] As of September 18, 2020, Spain had 625,651 cases and 30,405 deaths, including over 108,000 cases in Madrid. [4] Up to 15% of people infected with SARS-CoV-2 (COVID-19) require hospitalization for clinical care, including oxygen therapy; of those, approximately 5% require intensive care units (ICU). [5] Acute respiratory failure (ARF) is the leading cause of death. [6] COVID-19 is a respiratory infection that can quickly progress to dyspnea, tachypnea, and oxygen desaturation. [7] Hypoxemic and hypercapnic distress can follow, resulting from a diffuse interstitial lung process with severe alteration of the ventilation-perfusion relationship and inhibition of the compensatory mechanism of hypoxic pulmonary vasoconstriction, further deepening hypoxemia and resulting in acute respiratory distress syndrome (ARDS). [8] For respiratory management of patients in respiratory distress, treatments range from conventional oxygen therapy to advanced support with extracorporeal membrane oxygenation (ECMO).

Intermediate modes of ventilatory assistance include both invasive mechanical ventilation (IMV) and non-invasive ventilation (NIV). [9] When maximum fraction of inspired oxygen (FiO 2 ) is achieved, the only alternative to improve oxygenation is to increase the mean pressure in the airway through positive endexpiratory pressure (PEEP) or continuous positive airway pressure (CPAP) devices. [10] During the peak pandemic period, over about 3 to 4 weeks from mid-March to early April 2020, The use of NIV during the pandemic had not been universally adopted, in part because of concerns that health personnel might acquire infection given the high probability of such devices generating aerosols. [11] However, due to the lack of mechanical ventilators and the large numbers of patients in need of ventilatory support, the benefits of implementing NIV for ARF were greater than the potential risk of transmission of infection to healthcare workers with appropriate personal protective equipment (PPE).

We report here our use and evaluation of a newer nasal CPAP device for non-invasive ventilation of hospitalized patients with ARDS/ARF due to presumed COVID-19. The device we used is a positive nasal airway pressure (PAP) ventilation device originally designed for short periods of time (<24h) in adult patients (>30 kg) during the process of sedation or anesthesia [12] and has not been specifically compared to traditional high-flow CPAP in the treatment of respiratory failure. The SuperNO 2 VA system operates using wall oxygen rather than high-flow oxygen devices. Its low-flow mechanics allowed us to provide ventilatory support using available resources without significant capital investment in equipment.

We encountered a series of consecutive patients in respiratory failure at a time when no other ventilation devices, such as HFNC, masks for NIV, or Mapleson type C circuits were available. To meet the ventilation demands of our patients in the context of pandemic-related equipment shortages, we adapted and used the SuperNO2VA™ device (Vyaire Medical, Mettawa, IL) to temporarily provide NIV support to these patients. The SuperNO 2 VA mask has a nasal bridge membrane and creates an airtight seal when placed over the patient's nose, directing the flow of gas to the upper airways, allowing the airway to remain open and preventing its collapse. The goal of the device is to improve oxygenation and J o u r n a l P r e -p r o o f ventilation by keeping the airway patent, providing positive pressure to the lower airways, and minimizing the shunt effect and alteration of the ventilation-perfusion ratio typical of respiratory distress. [13, 14] (Figures 1 and 2 ) If the patient did not tolerate or respond to the nasal CPAP device, other devices were selected for support including NIV with total face mask, other high-flow nasal CPAP device, or endotracheal intubation.

The Ethics Committee of the Hospital Ramón y Cajal, Ctra. de Colmenar Viejo waived the need for ethics approval and the need to obtain consent for the collection, analysis, and publication of the retrospectively obtained and anonymized data for this non-interventional study. The research was completed in compliance with the Declaration of Helsinki. [15] Given the small size of this convenience sample of patients, we did not attempt statistical interpretation other than descriptive statistics of means and percentages.

During three weeks, the SuperNO2VA device was used on 15 patients including five in the ward, seven in the ICU, and three post-extubation ICU. In two cases, we used the device combined with the prone position as recommended in the literature for awake and cooperative patients. [16, 17] .

The results of the device use in the 14 patients are reported in Table 1 . In our cohort, 11 were males and three were females. The average age was 61.5 years for both sexes, with ages ranging from 43-87 years. Cases were broadly classified as patients in moderate respiratory failure with persistent hypoxia despite Venturi mask or reservoir (three patients); patients who did not meet ICU admission criteria due to advanced age and/or multiple comorbidities (two patients); patients in the intermediate respiratory care unit, before or after an ICU stay (seven patients); and patients who had been extubated in an effort to avoid reintubation (two patients).

The goal of the use of the nasal CPAP system was to avoid intubation or reintubation in this cohort of patients with respiratory insufficiency at a time of resource shortages. In total, 10 of the 14 J o u r n a l P r e -p r o o f patients (71.4%) did not require tracheal intubation, including seven of the males and all three females.

Four patients deteriorated during treatment with SuperNO 2 VA, with two requiring intubation, one requiring reintubation, and one expiring. In two of the patients with successful use of NIV CPAP, the prone position was utilized. One patient experienced pain over the bridge of the nose related to the mask, requiring a different method of ventilation.

In the wake of the COVID-19 pandemic, our hospital, like many others, faced a crisis of space, equipment, and manpower. The number of patients in respiratory failure who needed ICU beds, ventilators, and high-flow oxygen exceeded our capacity. We were forced to improvise, so we used a nasal CPAP system that relied on wall oxygen for NIV to provide respiratory support for some of these patients. This was easy to implement using available equipment and staffing. We found that the SuperNO 2 VA system allowed us to provide ventilation sufficient to keep some patients out of the ICU and off invasive mechanical ventilation.

In our series of patients, the nasal CPAP device was used in cases with early respiratory failure or with significant comorbidities and poor prognosis. These were patients who failed with other noninvasive measures such as non-rebreather masks, Venturi masks, or high flow nasal cannula.

Indications for escalation of care to noninvasive ventilation/invasive mechanical ventilation were respiratory distress, poor gas exchange, other organ dysfunction, and the rate of change in their clinical condition. We also used SuperNO 2 VA in post-intubation and post-operative patients during recovery in order to free up ICU beds.

The use of this device as an interim therapy for acute respiratory failure has not been described.

We theorized that low-flow nasal CPAP would provide better respiratory support that standard oxygen therapy in a setting where high-flow oxygen and equipment were not available. Positive experiences with high-flow CPAP have been published by Sartini [18] and Sivaloganathan [19] . In the latter study, 103 J o u r n a l P r e -p r o o f patients who would have required endotracheal intubation and mechanical ventilation were treated with NIV. Over half were able to avoid intervention with invasive ventilation. A study by Thompson et al [20] evaluated out-of-hospital patients treated emergently for acute respiratory distress and impending respiratory failure. CPAP applied in the field was associated with intubation in only 20% of patients compared with 50% in oxygen therapy alone. Even without more detailed physiologic data on these patients, the results with our small series are promising. This is a low-flow system that runs with wall oxygen only, avoiding the high-flow oxygen systems with their associated costs and challenges.

While we were not certain that oxygenation would be adequate, we were impressed with its effectiveness and ease of use. As would be expected for a nasal CPAP device, the SuperNO 2 VA device has known concerns of leak [21] , patient tolerance, and nasal bridge pain. Nonetheless, of our 14 patients with respiratory failure, NIV using the SuperNO 2 VA was successful in 10.

The authors are aware that the patients in this study are clinically disparate and generally do not fall within a group demographic (differing levels of acuity, comorbidities, stages of disease, etc.), making interpretation of results quite difficult. Proper evaluation of the efficacy/utility of this tool would require grouping like-patients into distinct cohorts and comparing them to known other techniques (conventional CPAP, HFNC, mechanical ventilation, etc.). However, our case series is thought-provoking and should spur interest in identifying these key clinical characteristics that are best helped with such a tool. Our paper reports on a small number of patients, limiting its generalizability. The report is retrospective in nature and would benefit from an age-and acuity-matched control intervention group.

More detailed clinical data is not available to these authors at the time of this writing due to patient confidentiality laws. Such information describing criteria for intubation or avoidance of intubation would be helpful to establish objective statements about treatment success or failure using the SuperNO 2 VA.

Given these limitations, we did not attempt statistical interpretation other than descriptive statistics of means and percentages.

J o u r n a l P r e -p r o o f

In times of crisis when facing overwhelming needs of critically ill patients, adaptability and improvisation require exploring the use of all tools available to achieve the best possible results. The SuperNO 2 VA device does not need specialized equipment or personnel and is inexpensive compared to other ventilation devices, which saves resources. Although the SuperNO 2 VA was not originally developed for the management of ARDS/ARF related to COVID-19, its mechanism allowed us, during a time of precarious resources, to improve the oxygenation and clinical situation in some patients with favorable results without the use of ICU beds.

The authors would like to thank Edward A. Rose, M.D., of Twenty Poms, LLC, Medical Writing Services for his assistance with preparaton of this manuscript. Dr. Rose's assistance was paid for by Vyaire Medical.

Vyaire Medical supported manuscript translation and development but had no influence of the content, case selection, case analyses, or study design. 

for Disease Control and Prevention. Information for Healthcare Professionals about Coronavirus (COVID-19)

Confirmado el primer caso de coronavirus en Madrid

World Health Organization. Novel Coronavirus(2019-nCoV) Situation

Coronavirus Resource Center

Care for Critically Ill Patients With COVID-19

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine

The coronavirus pandemic and aerosols: Does COVID-19 transmit via expiratory particles?

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

COVID-19 pneumonia: different respiratory treatments for different phenotypes

Less is More" in mechanical ventilation

Characterization of Aerosols Generated During Patient Care Activities

SuperNO2VA™ Nasal PAP Ventilation System

Nasal positive pressure with the SuperNO 2 VA™ device decreases sedation-related hypoxemia during prebariatric surgery EGD

Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment

WMA Declaration of Helsinki -Ethical Princiiples for Medical Research Involving Human Subjects

Prone positioning combined with high-flow nasal cannula in severe noninfectious ARDS

Prone positioning improves oxygenation in spontaneously breathing nonintubated patients with hypoxemic acute respiratory failure: A retrospective study

Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit

Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre

Out-of-hospital continuous positive airway pressure ventilation versus usual care in acute respiratory failure: a randomized controlled trial

Validation of Novel Completely Sealed Nasal Positive Airway Pressure Device: SuperNO2VA™ EtCO2 Measurement and Pressure Test Performance